Hsbc Holdings PLC Invests $60.90 Million in IQVIA Holdings Inc. $IQV

Hsbc Holdings PLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 315,338 shares of the medical research company’s stock, valued at approximately $60,904,000. Hsbc Holdings PLC owned approximately 0.19% of IQVIA as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of IQV. Apella Capital LLC grew its holdings in IQVIA by 5.1% in the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock worth $211,000 after purchasing an additional 58 shares during the period. Quadrant Capital Group LLC boosted its position in shares of IQVIA by 1.3% during the 4th quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock worth $1,080,000 after purchasing an additional 60 shares in the last quarter. Private Advisor Group LLC grew its stake in shares of IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after buying an additional 63 shares during the period. Breakwater Capital Group increased its position in IQVIA by 3.2% in the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after buying an additional 64 shares in the last quarter. Finally, Keybank National Association OH increased its position in IQVIA by 0.7% in the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock valued at $2,052,000 after buying an additional 67 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. TD Cowen upped their price objective on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Robert W. Baird raised their price objective on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Finally, Royal Bank Of Canada upped their target price on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

Insiders Place Their Bets

In other IQVIA news, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This trade represents a 29.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares of the company’s stock, valued at $5,232,110.84. The trade was a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 12,913 shares of company stock worth $3,098,793 over the last three months. Corporate insiders own 1.70% of the company’s stock.

IQVIA Stock Up 0.8%

IQV opened at $261.57 on Thursday. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $262.51. The company has a market cap of $43.05 billion, a PE ratio of 32.45, a price-to-earnings-growth ratio of 2.22 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a 50 day moving average of $218.41 and a 200 day moving average of $188.59.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA’s revenue was up 8.7% compared to the same quarter last year. During the same period last year, the business earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its board has approved a share buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.